2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare shares are currently in the red on Thursday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.2% and the broader S&P/ASX 200 Index (ASX: XJO) 0.18% lower.

However, two ASX healthcare shares are bucking the trend. One is rising on the back of a company update, while the other is likely continuing northwards due to positive momentum.

Let's check out the details.

2 ASX healthcare shares bucking the trend today

Race Oncology Ltd (ASX: RAC)

The Race Oncology share price lifted 5.88% to $1.44 shortly after the market opened on Thursday. This followed news of the successful completion of a drug discovery program.

Race Oncology shares have since fallen back to $1.39, up 2.21%.

The clinical-stage cancer drug biotech announced today that a program using NMR-based fragment screening had identified 39 molecular candidates (also called 'hits') that bound themselves to an m6A RNA demethylase protein called the FaT and Obesity-associated protein (FTO).

These hits have never been seen before or used in any previously reported FTO inhibitors.

FTO is one of the key proteins in the RNA regulatory system. It controls m6A RNA levels. Dysregulation of RNA epigenetics is a key driver of several metabolic diseases and many cancers.

Race said the successful testing would allow for the development of novel and patentable molecules.

These would have the potential to become new drugs specifically targeting the m6 A RNA epigenetic pathway.

There is much industry interest in developing FTO inhibitor drugs as potential new cancer treatments.

Race said the successful testing was "a major milestone" in its development of new FTO inhibitors that were "structurally distinct" from known FTO inhibitors. This means Race can develop patentable leads.

Race said it now "has a clear opportunity" to be the first to the clinic with a purpose-built, targeted FTO inhibitor that might have utility beyond cancer".

Race's Vice President of Research, Prof. Mike Kelso, commented:

Identification of chemical 'hits' that bind to a protein target of interest is a critical step in modern drug discovery.

Our successful FTO program at Monash provides Race with valuable new IP in the RNA epigenetics space, an enormously exciting area at the cutting-edge of oncology research and drug development.

Race said the next step would be a 'hit-to-lead' medicinal chemistry program. It described this as "an expensive undertaking", with the company currently evaluating its options.

The ASX healthcare share has climbed 63.5% in 2024 so far and is up 52.75% over the past 12 months.

Sigma Healthcare Ltd (ASX: SIG)

The Australian pharmaceutical distributor and wholesaler has no official news for the market today.

However, the ASX healthcare share rose by as much as 4.3% during intraday trading to a high of $2.42. The Sigma Healthcare share price is currently $2.40, up 3.45%.

A likely driver of today's share price rise is the ongoing momentum generated by Sigma's proposal to merge with Chemist Warehouse.

Investors are excited about this prospect, with the ASX healthcare share up by about 225% since news of the proposal broke on 11 December last year.

Earlier this month, the Australian Competition & Consumer Commission (ACCC) announced it would not oppose the merger. Investors are now awaiting further news as the merger plans progress.

The ASX healthcare share is up 140% in the year to date and up almost 253% over the past 12 months.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »